Fundz

Real-time funding, M&A, exec moves & hiring — the signals that move deals

The intelligence a $25K terminal charges for — the day it breaks, in your market, at a fraction of the price.

The funding market, moving in real timeBook a DemoChoose your plan
Loading live signals…

Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.

Back to SEC Filings
Material AgreementItem 1.01 · 8-KLOW RiskNeutral

DARE BIOSCIENCE, INC.

Filed: Mar 6, 2026CIK: 0001401914
Watch CompanyView on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Daré Bioscience completed the second closing of its Regulation A offering on March 6, 2026, issuing 17,500 Investor Units at $5.00 per unit for $87,500 in proceeds. This capital raise supports the company's growth initiatives as part of a broader offering of up to 4,854,000 units.

Key Takeaways

Second closing of Reg A offering completed with issuance of 17,500 Investor Units

Each unit comprises one share of Series A Convertible Preferred Stock and two common stock warrants

2 more takeaways

Filing Overview

Form Type8-K
Filing DateMar 6, 2026
Item1.01
CategoryMaterial Agreement
CIK0001401914
Accession #001-36395
Risk LevelLOW
SentimentNeutral
Signalinformational
Topics
stock offering

What This Means

The company entered into a significant agreement that could materially affect its business. This often signals new partnerships, licensing deals, or major contracts.
View Full Filing on SEC.govBrowse More Filings